LYSAKER, Norway—Preliminary findings of a study conducted on MenaQ7® show the vitamin K2 ingredient has positive effects on several cardiovascular disease (CVD) parameters and plays positive role in bone health. According to NattoPharma, which supplies the ingredient, the three-year clinical intervention study showed MenaQ7 improved pulse wave velocity, signifying heart benefits, and better conserved bone density and quality in postmenopausal women.
NattoPharma initiated the study in 2007, and the company said it expects full results to be available later in 2012. Recruitment for the study started in early 2008 and the last measurements were completed in fall 2011. In April 2008, NattoPharma started the study with 244 postmenopausal women randomized to receive either MenaQ7® or placebo. The was conducted at VitaK at the Maastricht University in the Nederland’s and led by Associate Professor of Biochemistry Cees Vermeer. The aim of the study was to investigate the effects of a sustained intake of a low-dose (180 mcg) of natural vitamin K2 (MenaQ7) on both bone and vascular health parameters.
The compliance rate among the participants was 91.4 percent, according to the company.
“The results from the three-year human study on MenaQ7® are encouraging," said CEO Peter Carlsson. "This is the first time in history such effects have been scientifically documented with natural vitamin K2." He said NattoPharma will use the findings to improve its commercial platform and expand partnerships with companies commercializing MenaQ7® in the supplement and functional food markets throughout the world.
MenaQ7 provides natural vitamin K2 as a fermentation extract manufactured by using Bacillus subtilis natto. It has previously shown benefits to heart and bone health.